Arbutus Biopharma Corp (ABUS) — 8-K Filings

8-K Filings (31)

• Arbutus Biopharma Files 8-K — Apr 15, 2026 Risk: low
  Arbutus Biopharma Corp. filed an 8-K on April 15, 2026, reporting other events and financial statements/exhibits as of April 14, 2026. The filing includes a pre
• 8-K Filing — Dec 11, 2025
• 8-K Filing — Nov 13, 2025
• Arbutus Biopharma Files 8-K — Oct 7, 2025 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on October 7, 2025, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceu
• Arbutus Biopharma Corp. Files 8-K — Sep 10, 2025 Risk: low
  Arbutus Biopharma Corp. filed an 8-K on September 10, 2025, reporting on other events and financial statements. The filing indicates a change in the company's p
• Arbutus Biopharma Files 8-K on Operations and Personnel — Aug 6, 2025 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on August 6, 2025, reporting on events as of August 4, 2025. The filing covers results of operations and financial co
• Arbutus Biopharma Terminates Material Definitive Agreement — Jun 25, 2025 Risk: medium
  Arbutus Biopharma Corp. announced on June 20, 2025, the termination of a material definitive agreement. The company, formerly known as Tekmira Pharmaceuticals C
• Arbutus Biopharma Files 8-K on Shareholder Vote Matters — May 23, 2025 Risk: low
  Arbutus Biopharma Corp. filed an 8-K on May 23, 2025, reporting on matters submitted to a vote of security holders as of May 21, 2025. The filing indicates a ch
• Arbutus Biopharma Files 8-K on Operations and Financials — May 14, 2025 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on May 14, 2025, reporting on its results of operations and financial condition. The filing also includes financial s
• Arbutus Biopharma Files 8-K — May 7, 2025 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on May 7, 2025, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceutica
• Arbutus Biopharma Files 8-K — Apr 23, 2025 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on April 23, 2025, reporting on other events and financial statements. The company, formerly known as Tekmira Pharmac
• Arbutus Biopharma Corp. Announces Board and Executive Changes — Apr 3, 2025 Risk: medium
  Arbutus Biopharma Corp. announced on March 28, 2025, changes related to its board of directors and executive compensation. Specifically, the company reported th
• Arbutus Biopharma Files 8-K on Financials — Mar 27, 2025 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on March 27, 2025, reporting on its results of operations and financial condition. The filing also includes financial
• Arbutus Biopharma Corp Files 8-K Report — Mar 3, 2025 Risk: medium
  On March 3, 2025, Arbutus Biopharma Corporation filed an 8-K report detailing a material definitive agreement. The filing also includes other events and financi
• Arbutus Biopharma Corp Files 8-K on Director/Officer Changes — Feb 25, 2025 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on February 25, 2025, reporting on the departure of a director, the election of new directors, and the appointment of
• Arbutus Biopharma Files 8-K — Jan 13, 2025 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on January 13, 2025, reporting on its results of operations, financial condition, and other events. The filing also i
• Arbutus Biopharma Files 8-K — Nov 15, 2024 Risk: low
  Arbutus Biopharma Corp. filed an 8-K on November 15, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceutica
• Arbutus Biopharma Files 8-K — Nov 6, 2024 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on November 6, 2024, reporting on its results of operations, financial condition, and other events. The filing includ
• Arbutus Biopharma Files 8-K — Oct 15, 2024 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on October 15, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmace
• Arbutus Biopharma Reports Director Changes and Compensation — Oct 11, 2024 Risk: medium
  Arbutus Biopharma Corp. filed an 8-K on October 11, 2024, reporting changes in its board of directors and executive compensation arrangements. The filing also i
• Arbutus Biopharma Files 8-K for Regulation FD Disclosure — Aug 5, 2024 Risk: low
  Arbutus Biopharma Corp. filed an 8-K on August 5, 2024, to report a Regulation FD Disclosure. The filing does not contain specific details about the nature of t
• Arbutus Biopharma Files 8-K with Operational Updates — Aug 1, 2024 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on August 1, 2024, reporting on results of operations, other events, and financial statements. The filing also notes
• Arbutus Biopharma Files 8-K, Changes Address — Jun 6, 2024 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on June 6, 2024, to report other events and financial statements. The filing indicates a change in the company's prin
• Arbutus Biopharma Files 8-K — Jun 5, 2024 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on June 5, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceutic
• Arbutus Biopharma Corp. Announces Board and Executive Changes — May 28, 2024 Risk: medium
  Arbutus Biopharma Corp. announced on May 22, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure o
• Arbutus Biopharma Corp Files 8-K — May 22, 2024 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on May 22, 2024, reporting other events and financial statements. The filing also notes the company's former name was
• Arbutus Biopharma Appoints New CEO, Dr. Sofia — May 2, 2024 Risk: medium
  Arbutus Biopharma Corporation announced on May 1, 2024, a change in its board of directors. Specifically, Dr. Michael J. Sofia has been appointed as the new Chi
• Arbutus Biopharma Files 8-K — Apr 4, 2024 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on April 4, 2024, reporting other events and financial statements. The company, formerly known as Tekmira Pharmaceuti
• Arbutus Biopharma Files 8-K on Financial Condition — Feb 29, 2024 Risk: low
  Arbutus Biopharma Corporation filed an 8-K on February 29, 2024, reporting on its financial condition and other events. The company, incorporated in British Col
• Arbutus Biopharma Confirms Nasdaq Listing for ABUS Common Shares — Jan 8, 2024
  Arbutus Biopharma Corporation filed an 8-K on January 8, 2024, to report on its current status, including its registration of Common Shares, without par value,
• Arbutus Biopharma Reports Executive Changes, Compensation on Dec 31 — Jan 4, 2024
  Arbutus Biopharma Corp filed an 8-K on January 4, 2024, reporting an event on December 31, 2023, related to changes in directors or officers and their compensat

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX